Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its fourth-quarter financial results on February 22, 2024, and host a conference call to discuss the corporate update. The press release and webcast will be accessible on the company's website. A recorded version of the call will be available for 30 days.
02/01/2024 - 04:05 PM
SAN FRANCISCO --(BUSINESS WIRE)--
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio . Participants may access the conference call via webcast on the Events & Presentations page of Vir’s website at https://investors.vir.bio/events-presentations . A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions. Vir has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208205237/en/
Media
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1 314-368-5189
Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
sdamouni@vir.bio
Source: Vir Biotechnology, Inc.
When will Vir Biotechnology release its fourth-quarter financial results?
Vir Biotechnology will release its fourth-quarter financial results on February 22, 2024.
What is the ticker symbol for Vir Biotechnology?
The ticker symbol for Vir Biotechnology is VIR.
Where can I access the corporate update and financial results?
The corporate update and financial results will be accessible on the Vir Biotechnology website under the Press Releases section.
How can I access the conference call?
Participants can access the conference call via webcast on the Events & Presentations page of Vir’s website.
How long will the recorded version of the conference call be available?
The recorded version of the call will be available on the website for 30 days after the completion of the event.
Vir Biotechnology Inc
NASDAQ:VIR
VIR Rankings
#5021 Ranked by Stock Gains
VIR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology
About VIR
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.